Yuki Tobisawa
Papers
9
Total Citations
62
H-Index
5
About
Yuki Tobisawa is a urologic surgeon and researcher whose work centers on advancing surgical and oncological outcomes for patients with prostate and bladder cancers. His primary research areas include robot-assisted radical prostatectomy and cystectomy, neoadjuvant chemohormonal therapy, and the development of novel biomarkers for surgical damage. Tobisawa has made significant contributions by demonstrating the feasibility and oncological safety of combining neoadjuvant chemohormonal therapy with robot-assisted surgery for high-risk and oligometastatic prostate cancer, as well as for muscle-invasive bladder cancer. His most cited work, on total cell-free DNA as a biomarker for surgical damage evaluation (13 citations), introduces a promising tool for perioperative assessment. He has also investigated technical refinements in robotic partial nephrectomy, comparing single- versus double-layer renorrhaphy. With multiple papers published between 2016 and 2025, Tobisawa’s cumulative impact is reflected in citations across his studies on neoadjuvant regimens, surgical techniques, and perioperative outcomes. His work is particularly valuable for clinicians seeking to optimize multimodal treatment strategies for high-risk urologic malignancies.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9